S&P/ASX 200 index to pop Tuesday morning – stocks to watch
Drew Meredith, CFP
June 30, 2020
The S&P/ASX 200 (INDEXASX: XJO) is expected to jump this
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (INDEXASX: XJO) is expected to jump this
CSL (ASX:CSL) has announced a US$450 million acquisition to the
The chief financial officer (CFO) of CSL (ASX:CSL) has left
CSL (ASX:CSL) has announced an acquisition to the market this
The S&P/ASX 200 (INDEXASX: XJO) is tipped to open slightly
Is the CSL (ASX:CSL) share price a buy after the
If you’re looking for the top ASX dividend income shares
Is CSL (ASX:CSL) the best COVID-19 recovery stock to buy
The latest of my “Never Sell stocks” is one of
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.